Mitsubishi UFJ Asset Management Co. Ltd. Buys 22,992 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 399,826 shares of the medical equipment provider’s stock after acquiring an additional 22,992 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.20% of Zimmer Biomet worth $39,383,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Zimmer Biomet by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock worth $2,120,751,000 after purchasing an additional 198,370 shares during the period. Dodge & Cox lifted its holdings in shares of Zimmer Biomet by 12.9% in the second quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock valued at $2,015,510,000 after purchasing an additional 2,533,009 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Zimmer Biomet by 8.7% in the second quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock valued at $520,752,000 after purchasing an additional 458,903 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Zimmer Biomet by 1.4% during the second quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock worth $465,480,000 after buying an additional 69,485 shares during the period. Finally, Primecap Management Co. CA grew its holdings in shares of Zimmer Biomet by 0.6% during the second quarter. Primecap Management Co. CA now owns 4,710,830 shares of the medical equipment provider’s stock worth $429,675,000 after buying an additional 27,860 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Down 2.5%

Shares of ZBH stock opened at $98.42 on Friday. Zimmer Biomet Holdings, Inc. has a 52-week low of $84.59 and a 52-week high of $114.44. The stock has a market cap of $19.25 billion, a price-to-earnings ratio of 27.80, a PEG ratio of 2.01 and a beta of 0.62. The firm’s 50-day moving average is $91.52 and its 200-day moving average is $95.91. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. During the same quarter in the previous year, the business earned $2.31 earnings per share. The business’s revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 27.12%.

Analyst Upgrades and Downgrades

ZBH has been the topic of several research reports. Stifel Nicolaus set a $110.00 target price on Zimmer Biomet in a research note on Wednesday, November 5th. Robert W. Baird reiterated a “neutral” rating and issued a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. Sanford C. Bernstein boosted their price objective on shares of Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research report on Friday, January 9th. Citigroup restated a “buy” rating on shares of Zimmer Biomet in a report on Wednesday, February 11th. Finally, Wall Street Zen lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $106.20.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.